Quiz
Article
Clinical Quiz: Anaphylaxis Management and Epinephrine Use
Author(s):
Key Takeaways
- The 2023 AAAAI update highlights diverse anaphylaxis presentations and the diagnostic role of biomarkers like tryptase.
- Early epinephrine administration is crucial, with delayed use linked to worse outcomes; barriers to its use are addressed.
In this quiz, we test your knowledge of evidence-based management strategies, recommended epinephrine doses, and evolving guidance on patient follow-up and discharge planning for anaphylaxis.
Credit: HCPLive
The 2023 update to the American Academy of Allergy, Asthma & Immunology (AAAAI) Practice Parameter on Anaphylaxis provides updated clinical recommendations on recognizing anaphylaxis across diverse clinical presentations and the utility of biomarkers, such as tryptase, in aiding diagnosis. This review served as a high-level summary of the 2023 practice parameter with evidence uncovered since the 2015 practice parameter.
Epinephrine remains the first-line treatment for anaphylaxis, with delayed administration associated with worse outcomes. The 2023 AAAAI Practice Parameter Update reinforces the importance of early and appropriate epinephrine use while addressing common barriers to administration.
Additionally, the guidelines refine best practices in adjunctive therapies, observation periods, and patient education post-reaction. In this quiz, we will test your knowledge of evidence-based management strategies, recommended dosing of epinephrine, and evolving guidance on patient follow-up and discharge planning.
Question 1 (Multiple Choice): What is the first-line treatment for anaphylaxis?
Editor’s note: This quiz was composed with the assistance of AI tools.
References
Wang J, Lieberman JA, Wallace DV, Waserman S, Golden DBK. Anaphylaxis in Practice: A Guide to the 2023 Practice Parameter Update. J Allergy Clin Immunol Pract. 2024;12(9):2325-2336. doi:10.1016/j.jaip.2024.06.036
